50 Key Biopharmaceutical and Biotechnology Companies
Biopharmaceutical companies bring to market products that hold great promise for treating some of the most intractable medical conditions such as cancer and autoimmune disease. Biotech opportunities largely mirror those in the pharmaceutical industry. The key difference is that biotech firms are much more focused on research because they are still developing their initial products.
50 Key Biopharmaceutical and Biotechnology Companies is a comprehensive look at the top 50 companies that are shaping the biotherapeutics market in 2017 and beyond. The top 50 companies in this report were chosen for a variety of reasons, including sales of marketed biopharmaceutical products, innovation in biotherapeutics, and unique additions to the market, either marketed products or products in development.
50 Key Biopharmaceutical and Biotechnology Companies profiles the market leaders in-depth, presenting detailed information about each company, including:
- a Corporate Summary
- Selected Biopharmaceutical Products
- Biopharmaceuticals in Development
- Selected Corporate Developments
- Company Financials
- Regional Revenue Breakdown by Percentage (%)
This report includes profiles of large traditional pharma powerhouses such as Pfizer, Novartis, Roche, Merck, GSK, Bristol-Myers Squibb, Bayer, and others; but it also includes smaller niche companies such as Genmab, Seattle Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and others.